In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SanoGene Therapeutics Inc.

www.sanogene.com

Latest From SanoGene Therapeutics Inc.

Through the Palace Walls: Blood-Brain Barrier Transport Technologies

Delivering compounds across the blood-brain barrier remains the rate limiting step in brain-drug development, yet the problem generally gets ignored until it's too late. Several biotechs are bringing novel strategies to finding a solution, focusing especially on brain cancers. Success may open the floodgates of CNS drug development.
BioPharmaceutical

SanoGene Therapeutics Inc.

SanoGene Therapeutics thinks it will be able to enhance outcomes for glioblastoma patients by following the unavoidable brain surgery with an injection of targeted plasmids containing short sequences of RNA.
BioPharmaceutical Research and Development Strategies

Glioblastoma Start-Ups Get Specific

For start-ups developing novel and risky medicines to treat glioblastoma, a rare, invasive form of brain cancer, the Pfizer/Avant deal was a watershed moment: It signaled the vigorous interest of a pharmaceutical behemoth in a disease where patients number in just the tens of thousands. The positive effects are likely to be felt in executive suites of biotechs developing therapeutics for this grievous disease.
BioPharmaceutical Business Strategies

Start-Up Previews (07/2008)

A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Glioblastoma Start-Ups Get Specific," "Glaucoma Start-Ups Reach Critical Mass," and "ALS on the Cusp." Plus these Start-Ups Across Health Care: EarlySense, NeoChord, and Pantec Biosolutions.
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • SanoGene Therapeutics Inc.
  • Senior Management
  • Caralynn V Nowinski, MD, Acting CEO
  • Contact Info
  • SanoGene Therapeutics Inc.
    Phone: (312) 927-3570
    c/o ARCH Dev. Partners, 20 North Wacker
    Ste. 2000
    Chicago, IL 60606
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register